Characteristics and outcome of AIDS-related Hodgkin

Characteristics and outcome of AIDS-related Hodgkin Veliparib concentration lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47: 422–428. 49 Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: E22–25. 50 Cingolani A, Torti L, Pinnetti C et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS 2010; 24: 2408–2412.

51 Mounier N, Katlama C, Costagliola D et al. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Crit Rev Oncol Hematol 2009; 72: 10–20. 52 Rubinstein PG, Braik T, Jain S et al. Ritonavir based highly active retroviral therapy (HAART) correlates with early neurotoxicity

when combined with ABVD treated HIV associated Hodgkin lymphoma but not non-Hodgkin lymphoma. A retrospective study. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 2807. 53 Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993; 341: click here 1051–1054. 54 Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065–2071. 55 Gabarre J, Marcelin AG, Azar N et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004; 89: 1100–1108. 56 Serrano D, Carrion Nintedanib (BIBF 1120) R, Balsalobre P et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol

2005; 33: 487–494. 57 Krishnan A, Molina A, Zaia J et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105: 874–878. 58 Re A, Cattaneo C, Michieli M et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21: 4423–4427. 59 Spitzer TR, Ambinder RF, Lee JY et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008; 14: 59–66. 60 Diez-Martin JL, Balsalobre P, Re A et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009; 113: 6011–6014.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>